The next cell therapy move takes Astra into neoantigens
For $200m Astrazeneca buys Neogene, and Alaunos’s long-suffering investors can just look on.
Gossamer could put pressure on Merck
The pharma giant leads the pulmonary arterial hypertension pipeline, but other potentially disease-modifying treatments are in the works.
AHA 2022 – Amgen looks good in metabolic disease
With a mid-stage win in cholesterol lowering in the bag, attention turns to obesity.
Ash 2022 preview – a new multiple myeloma mechanism makes a splash
Talquetamab gets top billing in Ash’s press programme, but the data raise important issues about the role of targeting GPRC5D.
Looking for winners in geographic atrophy
NGM’s NGM621 now looks like a dead end, but there are plenty of others hoping for a piece of this market, including Roche and Lineage.
